Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
For more information about the trial above please contact the study team:
Principal Investigator, Mariam Alexander, at firstname.lastname@example.org.
Study Coordinator, Alexandra Leitner, at email@example.com, or please call +1 843-792-1507.
Trial opened at the following institutions: Medical University of South Carolina